- The AKRO stock gained more than 129 per cent on September 13.
- Its trading volume was more than 17 million on Tuesday morning.
- Akero Therapeutics had a market cap of about US$ 1.02 billion.
The Akero Therapeutics, Inc. (NASDAQ: AKRO) stock notched a place among the top movers in pre-market and morning trading on September 13.
The price of the AKRO stock rocketed more than 129 per cent in the morning trading on Tuesday after closing at over four per cent up in the prior session, suggesting that the investors have turned their focus to the stock.
So what could have spurred the rally in the AKRO stock on Tuesday? Let's explore with Kalkine Media®.
Why is it rising?
The market participants appear to have lauded the clinical-stage biotechnology firm's recent release about its Phase 2b HARMONY study.
The California-based company unveiled its topline data from a Phase 2b study. The study was continued for 24 weeks to assess the potential and safety measures of efruxifermin (EFX).
Notably, efruxifermin (EFX) is its lead product candidate, which was utilized on patients with NASH or nonalcoholic steatohepatitis.
According to the announcement, both the 50 mg and 28 mg dose groups of its lead product candidate fulfil the primary endpoint with 41 per cent and 39 per cent of EFX-treated patients, respectively.
The study showed that the patients had experienced at least a single stage of liver fibrosis improvement, and no worsening of NASH was seen by the final week.
Source: ©Kalkine Media®; © Canva via Canva.com
The AKRO stock was priced at US$ 28.135 at 9:45 am ET on September 13, an increase of 129.30 per cent from its previous close of US$ 12.27. Its price closed at 4.78 per cent higher in the last session.
Meanwhile, more than 17.13 million shares of AKRO have been exchanged at the time of writing. During pre-market hours, its price soared to give it a market cap of about US$ 848 million, while at its trading price during writing, its market cap rose to US$ 1.02 billion.